Compare · MYO vs SNN
MYO vs SNN
Side-by-side comparison of Myomo Inc. (MYO) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $13.31B, about 262.9x MYO ($50.6M).
- Over the past year, MYO is down 46.2% and SNN is up 3.3% - SNN leads by 49.4 points.
- SNN has been more active in the news (13 items in the past 4 weeks vs 11 for MYO).
- SNN has more recent analyst coverage (23 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- Smith & Nephew SNATS Inc.
- Price
- $1.55+17.42%
- $31.08-0.77%
- Market cap
- $50.6M
- $13.31B
- 1M return
- +87.18%
- +6.74%
- 1Y return
- -46.18%
- +3.26%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 11
- 13
- Recent ratings
- 3
- 23
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest MYO
- Chief Commercial Officer Mitchell Micah covered exercise/tax liability with 6,529 shares, decreasing direct ownership by 6% to 102,949 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 7,635 shares, decreasing direct ownership by 7% to 100,983 units (SEC Form 4)
- Chief Financial Officer Henry David A covered exercise/tax liability with 10,050 shares, decreasing direct ownership by 2% to 435,124 units (SEC Form 4)
- Director Kirk Thomas F bought $50,803 worth of shares (40,002 units at $1.27), increasing direct ownership by 6% to 693,865 units (SEC Form 4)
- Amendment: Chief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)
- Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)
- SEC Form SD filed by Myomo Inc.
- Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)
- Director Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)
Latest SNN
- A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
- Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith & Nephew downgraded by Kepler
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching